Fontanelli A, Falcini F, Lippi G, Lucente E, Morelli P, Viliani T, Nuzzaci G, Massi G B
Unità di Chimica e Microscopia Clinica, Università degli Studi di Firenze.
Minerva Ginecol. 1992 May;44(5):251-5.
Eighty-one patients were submitted to gynaecological malignancy surgery in a randomized study aimed at the evaluation of the efficacy of defibrotide (40 patients) and calcium heparin (41 patients) in perioperative prophylaxis. They were randomly allocated to defibrotide group (400 mg bid im starting one day before surgery and continuing until the 7th postoperative day) or calcium heparin group (5000 IU bid sc starting two hours before surgery and continuing likewise for 7 days). No cases of DVT diagnosed by means of a Doppler CW were observed in either treatment group. Laboratory parameters have shown similar modifications in the two treatment groups. Three cases of bleeding were observed in the calcium heparin group while no cases of bleeding were detected in the defibrotide group. The results obtained suggest that defibrotide is at least as effective as calcium heparin in perioperative DVT prevention and that the former drug has a possibly better tolerability profile, due to a decisively lower tendency to bleeding.
在一项旨在评估去纤苷（40例患者）和钙肝素（41例患者）围手术期预防效果的随机研究中，81例患者接受了妇科恶性肿瘤手术。他们被随机分配到去纤苷组（术前1天开始，每日2次，每次400mg，肌肉注射，持续至术后第7天）或钙肝素组（术前2小时开始，每日2次，每次5000IU，皮下注射，同样持续7天）。两个治疗组均未观察到通过多普勒连续波诊断的深静脉血栓形成（DVT）病例。实验室参数在两个治疗组中显示出相似的变化。钙肝素组观察到3例出血病例，而去纤苷组未检测到出血病例。所获得的结果表明，去纤苷在围手术期预防DVT方面至少与钙肝素一样有效，并且由于出血倾向明显较低，前一种药物可能具有更好的耐受性。
